Ginkgo Bioworks Holdings, Inc.
DNAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ginkgo Bioworks Holdings, Inc. focuses on Biotechnology services and products. Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. The $672.7M market capitalization puts DNA squarely in small-cap range for its industry. It operates through the Cell Engineering and Biosecurity segments.
Market Cap
$672.7M
Beta
1.79
P/E (TTM)
—
P/E (Fwd)
-3.44
EPS (TTM)
$-5.06
EPS (Fwd)
$-2.90
ROE
-59.9%
ROA
-16.7%
Cash
$302.2M
Total Debt
$404.1M
Free CF
-$72.4M
52W Change
-25.4%
Annual Financials
Cash vs Debt
Where DNA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, DNA finished 37.75% above its 150-day moving average ($8.37) and 35.97% above its 200-day moving average ($8.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DNA overbought or oversold?
At the October 15, 2026 close, DNA's RSI(14) was 55.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ginkgo Bioworks Holdings, Inc. carries $404.1M in total debt against $302.2M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$72.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -59.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $477.7M (2022) to $170.2M (2025), a 64% decline worth watching.
Ginkgo Bioworks Holdings, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Ginkgo Bioworks Holdings, Inc. and its sector.